Our Insights Oncology Anthony Iannacci 1/29/20 Oncology Anthony Iannacci 1/29/20 PARP Inhibitors: Promise in New Maintenance Indications Read More Oncology Anthony Iannacci 12/16/19 Oncology Anthony Iannacci 12/16/19 Candidate Observations to Be Added to Equinox’s Oncology Normative Pricing Model Read More Oncology Anthony Iannacci 10/22/19 Oncology Anthony Iannacci 10/22/19 Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC Read More Oncology Anthony Iannacci 6/18/19 Oncology Anthony Iannacci 6/18/19 Calquence: The price is right Read More Chronic Disease Anthony Iannacci 6/11/19 Chronic Disease Anthony Iannacci 6/11/19 Radicava: Not Innovative Enough to Sustain Strong Start Read More Oncology, R&D Insights Anthony Iannacci 6/5/19 Oncology, R&D Insights Anthony Iannacci 6/5/19 How to Price an Oncology Drug Read More Chronic Disease Anthony Iannacci 3/29/19 Chronic Disease Anthony Iannacci 3/29/19 Hemlibra: A Strong Leader in Hemophilia A Read More Chronic Disease Anthony Iannacci 3/7/19 Chronic Disease Anthony Iannacci 3/7/19 Oral semaglutide: A game changer in type 2 diabetes Read More Chronic Disease Anthony Iannacci 2/6/19 Chronic Disease Anthony Iannacci 2/6/19 Tymlos: A new force in the osteoporosis market Read More Chronic Disease Anthony Iannacci 2/6/19 Chronic Disease Anthony Iannacci 2/6/19 Xeljanz: Is ulcerative colitis finally the place for JAKs to shine? Read More Oncology Anthony Iannacci 4/8/16 Oncology Anthony Iannacci 4/8/16 Imbruvica: Closing the window of opportunity in CLL Read More Oncology Anthony Iannacci 11/10/15 Oncology Anthony Iannacci 11/10/15 Keytruda: Exceptional early results in a small colorectal cancer population Read More Oncology Anthony Iannacci 10/31/15 Oncology Anthony Iannacci 10/31/15 Blincyto: High price for an undifferentiated drug Read More Chronic Disease Anthony Iannacci 10/23/15 Chronic Disease Anthony Iannacci 10/23/15 Gilenya, Aubagio, and Tecfidera in Multiple Sclerosis Read More Oncology Anthony Iannacci 10/15/15 Oncology Anthony Iannacci 10/15/15 PD-1 Inhibitors: Strong starts in three indications Read More Oncology Anthony Iannacci 9/16/15 Oncology Anthony Iannacci 9/16/15 Avastin: One molecule in multiple cancers Read More Chronic Disease Anthony Iannacci 9/5/15 Chronic Disease Anthony Iannacci 9/5/15 Jardiance: New outcomes data in type 2 diabetes Read More Oncology Anthony Iannacci 8/14/15 Oncology Anthony Iannacci 8/14/15 Kyprolis: A rapid rise in a crowded market Read More Chronic Disease Anthony Iannacci 2/20/14 Chronic Disease Anthony Iannacci 2/20/14 Brintellix: Another "me too" in major depression Read More Chronic Disease Anthony Iannacci 10/29/13 Chronic Disease Anthony Iannacci 10/29/13 Pradaxa: Stroke prevention in atrial fibrillation Read More Newer Posts Older Posts
Oncology Anthony Iannacci 1/29/20 Oncology Anthony Iannacci 1/29/20 PARP Inhibitors: Promise in New Maintenance Indications Read More
Oncology Anthony Iannacci 12/16/19 Oncology Anthony Iannacci 12/16/19 Candidate Observations to Be Added to Equinox’s Oncology Normative Pricing Model Read More
Oncology Anthony Iannacci 10/22/19 Oncology Anthony Iannacci 10/22/19 Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC Read More
Oncology Anthony Iannacci 6/18/19 Oncology Anthony Iannacci 6/18/19 Calquence: The price is right Read More
Chronic Disease Anthony Iannacci 6/11/19 Chronic Disease Anthony Iannacci 6/11/19 Radicava: Not Innovative Enough to Sustain Strong Start Read More
Oncology, R&D Insights Anthony Iannacci 6/5/19 Oncology, R&D Insights Anthony Iannacci 6/5/19 How to Price an Oncology Drug Read More
Chronic Disease Anthony Iannacci 3/29/19 Chronic Disease Anthony Iannacci 3/29/19 Hemlibra: A Strong Leader in Hemophilia A Read More
Chronic Disease Anthony Iannacci 3/7/19 Chronic Disease Anthony Iannacci 3/7/19 Oral semaglutide: A game changer in type 2 diabetes Read More
Chronic Disease Anthony Iannacci 2/6/19 Chronic Disease Anthony Iannacci 2/6/19 Tymlos: A new force in the osteoporosis market Read More
Chronic Disease Anthony Iannacci 2/6/19 Chronic Disease Anthony Iannacci 2/6/19 Xeljanz: Is ulcerative colitis finally the place for JAKs to shine? Read More
Oncology Anthony Iannacci 4/8/16 Oncology Anthony Iannacci 4/8/16 Imbruvica: Closing the window of opportunity in CLL Read More
Oncology Anthony Iannacci 11/10/15 Oncology Anthony Iannacci 11/10/15 Keytruda: Exceptional early results in a small colorectal cancer population Read More
Oncology Anthony Iannacci 10/31/15 Oncology Anthony Iannacci 10/31/15 Blincyto: High price for an undifferentiated drug Read More
Chronic Disease Anthony Iannacci 10/23/15 Chronic Disease Anthony Iannacci 10/23/15 Gilenya, Aubagio, and Tecfidera in Multiple Sclerosis Read More
Oncology Anthony Iannacci 10/15/15 Oncology Anthony Iannacci 10/15/15 PD-1 Inhibitors: Strong starts in three indications Read More
Oncology Anthony Iannacci 9/16/15 Oncology Anthony Iannacci 9/16/15 Avastin: One molecule in multiple cancers Read More
Chronic Disease Anthony Iannacci 9/5/15 Chronic Disease Anthony Iannacci 9/5/15 Jardiance: New outcomes data in type 2 diabetes Read More
Oncology Anthony Iannacci 8/14/15 Oncology Anthony Iannacci 8/14/15 Kyprolis: A rapid rise in a crowded market Read More
Chronic Disease Anthony Iannacci 2/20/14 Chronic Disease Anthony Iannacci 2/20/14 Brintellix: Another "me too" in major depression Read More
Chronic Disease Anthony Iannacci 10/29/13 Chronic Disease Anthony Iannacci 10/29/13 Pradaxa: Stroke prevention in atrial fibrillation Read More
